Alzamend Neuro (ALZN) Q2 2025 earnings summary

Executive summary

• Focused on developing AL001 and ALZN002 for Alzheimer's, BD, MDD, and PTSD, with both candidates in clinical stages and no revenue generated to date.

• Completed Phase IIA clinical trial for AL001 with positive topline data; full data set announced in October 2024.

• Announced partnership with Massachusetts General Hospital for upcoming clinical trials, including five Phase II trials for AL001 in 2025.

• Achieved significant financial improvement, moving from a stockholder deficit to $3.8 million in equity as of October 31, 2024.

• Increased cash position to $4.1 million, supporting upcoming clinical trials in 2025.

Financial highlights

• Net loss for the quarter ended October 31, 2024 was $1.4 million, a 53% improvement year-over-year.

• Net loss for the six months ended October 31, 2024 was $2.4 million, a 64% improvement year-over-year.

• Net cash provided by financing activities totaled $8.3 million for the six months ended October 31, 2024.

• Cash at October 31, 2024 was $4.1 million; working capital was $3.5 million.

• Stockholder equity improved to $3.8 million from a $2.6 million deficit at April 30, 2024.

Outlook and guidance

• Management expects continued net losses and negative cash flows until product commercialization.

• Preparing to initiate five Phase II clinical trials for AL001 in 2025 in partnership with Massachusetts General Hospital.

• ALZN002 Phase I/IIA trial to resume in 2025 after engaging a new clinical research organization.

• Current cash and anticipated financing are expected to meet requirements for the next twelve months, but substantial doubt remains about long-term going concern.

• Anticipates leveraging improved financial position to support clinical advancement and maintain Nasdaq listing compliance.